Curi Bio Recognized as a 2024 Deloitte Technology Fast 500 Winner
Saved in:
| Title: | Curi Bio Recognized as a 2024 Deloitte Technology Fast 500 Winner |
|---|---|
| Authors: | Curi Bio |
| Source: | Business Wire (English). 11/22/2024. |
| Abstract: | Curi Bio, a leader in delivering human functional data to drug discoverers through advanced preclinical tissue models, is proud to announce its selection as one of Deloitte's Technology Fast 500™ companies in 2024, an annual ranking of the 500 fastest-growing technology companies in North America. Curi Bio achieved an overall rank of #123 and secured #18 out of the 70 life sciences companies recognized, highlighting its transformative contribution to enabling the development of next-generation medicines. Curi Bio’s innovative human stem cell platforms deliver functional data that enable biopharmaceutical researchers to make better informed, data-driven decisions during preclinical drug development. [ABSTRACT FROM PUBLISHER] |
| Database: | Regional Business News |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Curi Bio, a leader in delivering human functional data to drug discoverers through advanced preclinical tissue models, is proud to announce its selection as one of Deloitte's Technology Fast 500™ companies in 2024, an annual ranking of the 500 fastest-growing technology companies in North America. Curi Bio achieved an overall rank of #123 and secured #18 out of the 70 life sciences companies recognized, highlighting its transformative contribution to enabling the development of next-generation medicines. Curi Bio’s innovative human stem cell platforms deliver functional data that enable biopharmaceutical researchers to make better informed, data-driven decisions during preclinical drug development. [ABSTRACT FROM PUBLISHER] |
|---|
